Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01922115 · ClinicalTrials.gov registry record · Phase 4
The Effect of Anticholinergics on Cognitive Function in the Elderly
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 4
- Development phase
- 59
- Enrollment target
NCT01922115 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 59 participants.
The verdict
NCT01922115, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 59 participants
- Enrollment target
Study Summary
Anticholinergic medication is used to treat overactive bladder (OAB). A known side effect of this medication is cognitive dysfunction. OAB is more prevalent in the elderly population - a group that also has a higher baseline risk of cognitive dysfunction. Our objective is to evaluate the effect of an anticholinergic medication on cognitive function in elderly women.
Interventions
- DRUG Placebo
- DRUG Trospium Chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01922115
The ClinicalTrials.gov registry entry for NCT01922115 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01922115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01922115 about?
NCT01922115 is a clinical study titled "The Effect of Anticholinergics on Cognitive Function in the Elderly". Anticholinergic medication is used to treat overactive bladder (OAB). A known side effect of this medication is cognitive dysfunction. OAB is more prevalent in the elderly population - a group that also has a higher baseline risk of cognitive dysfunction. Our objective is to evaluate the effect of a...
What is the current status of trial NCT01922115?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 59 participants. The study started on 2013-06. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01922115?
The interventions under investigation include: Placebo (DRUG), Trospium Chloride (DRUG).
Who is sponsoring clinical trial NCT01922115?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.